Karyopharm Therapeutics (KPTI) Total Current Liabilities (2012 - 2025)

Karyopharm Therapeutics has reported Total Current Liabilities for 14 years, with the latest figure at $92.1 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities changed 0.22% year-over-year to $92.1 million; the trailing twelve-month figure through Dec 2025 stood at $92.1 million (changed 0.22% YoY), and the FY2025 full-year result was $92.1 million, changed 0.22% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $92.1 million, up from $87.2 million in the prior quarter.
• The five-year high for Total Current Liabilities was $99.2 million in Q2 2025, with the low at $57.6 million in Q2 2024.
• Historically, Total Current Liabilities has averaged $70.8 million across 5 years, with a median of $65.6 million in 2022.
• Annual changes were most pronounced in 2022 — Total Current Liabilities fell 10.59% — and 2025, when it surged 72.19%.
• Karyopharm Therapeutics' Total Current Liabilities stood at $73.7 million in 2021, then fell by 10.59% to $65.9 million in 2022, then advanced by 5.42% to $69.5 million in 2023, then soared by 32.79% to $92.3 million in 2024, then retreated by 0.22% to $92.1 million in 2025.
• The last three Total Current Liabilities figures came in at $92.1 million (Q4 2025), $87.2 million (Q3 2025), and $99.2 million (Q2 2025), per Business Quant data.